scholarly journals Urinary C-Peptide Creatinine Ratio as a Non-Invasive Tool for Identifying Latent Autoimmune Diabetes in Adults (LADA)

2019 ◽  
Vol Volume 12 ◽  
pp. 2531-2537 ◽  
Author(s):  
Wei Liu ◽  
Xingquan Huang ◽  
Xiuying Zhang ◽  
Xiaoling Cai ◽  
Xueyao Han ◽  
...  
2009 ◽  
Vol 83 (2) ◽  
pp. e62-e65 ◽  
Author(s):  
Seung-Hwan Lee ◽  
Hyuk-Sang Kwon ◽  
Soon-Jib Yoo ◽  
Yu-Bai Ahn ◽  
Kun-Ho Yoon ◽  
...  

2015 ◽  
Vol 32 (3) ◽  
pp. 289-296 ◽  
Author(s):  
R. Buzzetti ◽  
P. Pozzilli ◽  
R. Frederich ◽  
N. Iqbal ◽  
B. Hirshberg

2021 ◽  
Vol 3 (2) ◽  
pp. 1
Author(s):  
Manoj Gedam ◽  
Dipti Sarma ◽  
Bipul Choudhury

To assess the correlation between urinary C peptide creatinine ratio with serum C peptide, serum insulin and its correlation with clinical and biochemical parameters of metabolic syndrome. A total of 100 subjects more than 18 years of age with metabolic syndrome according to ATP III criteria with 100 controls were included in a prospective observational study for a period of 1.5 years. Individual parameters of metabolic syndrome was higher in females with hypertriglyceridemia was most common and hyperglycaemia least common parameter of metabolic syndrome. Fasting urinary C peptide creatinine ratio and Stimulated urinary C peptide correlate significantly with fasting serum C peptide (p<0.01),stimulated serum C peptide (p<0.01), serum fasting insulin (p<0.01) and HOMA IR (p<0.01). A fasting urinary C peptide creatinine ratio of more than 1.8 nmol/mmol, stimulated urinary C peptide creatinine ratio more than 2.8 nmol/mmol and HOMA IR >2.7 can be used as a parameter to distinguish individual with and without metabolic syndrome. Urinary C peptide creatinine ratio correlate with serum C peptide and parameters of metabolic syndrome and can be used as a non-invasive simple tool to assess insulin resistance and also to distinguish patients with and without metabolic syndrome.


2019 ◽  
Vol 9 (3) ◽  
pp. 26-29
Author(s):  
Sagar R ◽  
Chandrudu J ◽  
Madhubhushan M ◽  
Seshaiah S

In adults, a fragment of diabetic individuals with βcell autoantibodies has initially non Insulin requiring diabetes clinically performing as type 2 diabetes mellitus (T2DM), named latent autoimmune diabetes in maturity (LADA) which on later years requires Insulin. LADA is either unnoticed or misdiagnosed in many cases. The occurrence GAD autoantibodies and positive levels of C-peptide analysis are tested to determine and finalize the patients’ Insulin dependency. The frequency of βcell autoantibodies (GAD) and C-Peptide analysis was determined in 31 Type 2 diabetic adults. The type of diabetes was classified by doing a Postprandial Blood Glucose test. Ten Type 1 diabetic patients and 10 ordinary people were also subjected to the three tests for comparative study. Twenty-three per cent of the adults with T2DM were tested positive for GAD autoantibody, and 61 per cent were tested positive (who came in T1DM range) for C-peptide analysis among them. 19% of the patients were tested positive for both GAD antibody and C-peptide analysis. Patients had the common symptoms of polyuria, polyphagia and polydipsia. In T2DM patients, 61% were females, and 39% were males, and all were non-obese. β‐cell autoantibodies were evident in a subcategory of initially non‐insulin needy diabetic adults with the clinical entrance of T2DM. This proves the existence and necessity for change in Insulin dependency.


Author(s):  
Malihe Mohammadi ◽  
Hossein Ali Khaza'i

Background and Aims: The prevalence of latent autoimmune diabetes in adults (LADA) among diabetic patients is less recognized and underdiagnosed. The aim of this study was to determine the prevalence of LADA in type 2 diabetic patients and to compare the characteristics of these two groups in Torbat-e Heydarieh, Iran. Materials and Methods: Totally, 198 male and 277 female patients diagnosed with type 2 diabetes are aged between 35 -70 years were selected and the glutamic acid decarboxylase antibodies (GADA) assessment was used for the diagnosis of LADA in them. GADA in their sera was measured by commercial anti-GAD enzyme-linked immunosorbent assay (ELISA) kit. In addition, blood pressure, sera C-peptide and cholesterol levels was measured and compared in the mentioned two groups. Demographic data including age, gender, age at diagnosis, family history of diabetes, Body mass index (BMI) and need for insulin therapy were collected from subjects and data were analyzed using SPSS software. Results: Of 475 patients, 53 ones (11.2%) were GADA positive. Significant difference was found between GADA positive and GADA negative patients in terms of mean age, C-peptide levels, cholesterol levels and need for insulin therapy to control the disease. As for gender, family history of diabetes, BMI value and hypertension there was no significant correlation between these two groups. Conclusion: The prevalence of LADA in diabetic patients was 11.2%. Presence of GAD antibodies in diabetic patients is related to reduced levels of C-peptide, increased cholesterol levels and the need for insulin during the follow-up.


Sign in / Sign up

Export Citation Format

Share Document